Abiopharma

🔍 Fulton Duncan (Executive)

Company: Restaurant Brands International Inc. (QSR)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Holds 0 shares of Common Shares (Direct)
  Date: 2026-04-02 | Code: H | shares_owned_after: 51,216.92
• Acquired 21 shares of Restricted Share Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,478.13 | transaction_form_type: 4 | Footnotes: F4, F5, F6, F6
• Acquired 44 shares of Restricted Share Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,193.49 | transaction_form_type: 4 | Footnotes: F4, F5, F7, F7
• Acquired 184 shares of Performance Share Units (Derivative)
  Date: 2026-04-02 | Code: A | Expires: 2027-03-15 | Exercise: 2027-03-15 | equity_swap_involved: 0 | shares_owned_after: 21,440.98 | transaction_form_type: 4 | Footnotes: F8, F9
• Acquired 42 shares of Restricted Share Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,919.45 | transaction_form_type: 4 | Footnotes: F4, F5, F10, F10
• Acquired 206 shares of Performance Share Units (Derivative)
  Date: 2026-04-02 | Code: A | Expires: 2028-03-15 | Exercise: 2028-03-15 | equity_swap_involved: 0 | shares_owned_after: 24,072.01 | transaction_form_type: 4 | Footnotes: F11, F9
• Acquired 60 shares of Restricted Share Units (Derivative)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,991.86 | transaction_form_type: 4 | Footnotes: F4, F5, F12, F12
• Acquired 188 shares of Performance Share Units (Derivative)
  Date: 2026-04-02 | Code: A | Expires: 2029-03-15 | Exercise: 2029-03-15 | equity_swap_involved: 0 | shares_owned_after: 21,982.21 | transaction_form_type: 4 | Footnotes: F13, F9
• Holds 60,000 shares of Option (Right to Buy) at $63.64 per share (Derivative)
  Date: 2026-04-02 | Code: H | Expires: 2028-08-03 | shares_owned_after: 60,000.00 | Footnotes: F1, F2
• Holds 15,000 shares of Option (Right to Buy) at $66.31 per share (Derivative)
  Date: 2026-04-02 | Code: H | Expires: 2030-02-21 | shares_owned_after: 15,000.00 | Footnotes: F3, F2

Footnotes:

• F1: The options were issued with an exercise price of CAD $82.81. The reported exercise price represents the U.S. dollar equivalent on the grant date.
• F2: These options are fully vested and exercisable.
• F3: The options were issued with an exercise price of CAD $88.03. The reported exercise price represents the U.S. dollar equivalent on the grant date.
• F4: Each restricted share unit represents a contingent right to receive one common share.
• F5: Represents dividend equivalent rights that accrued on the underlying award of restricted share units. Dividend equivalent rights accrue when and as dividends are paid on the common shares underlying the applicable restricted share units and vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted share units to which they relate.
• F6: These restricted share units vest in equal annual installments. The remaining vesting will occur on December 15, 2026.
• F7: These restricted share units vest in equal annual installments. The remaining vestings will occur on December 15, 2026 and December 15, 2027.
• F8: The shares reported represent an award of performance based restricted share units ("2024 PBRSUs") granted to the Reporting Person. The 2024 PBRSUs will have a performance period beginning February 23, 2024 and ending February 23, 2027 and to the extent earned will vest on March 15, 2027. The number of common shares that will be earned at the end of the performance period is subject to increase or decrease based on the results of the performance condition.
• F9: Represents dividend equivalent rights that accrued on the underlying award of performance based restricted share units. Dividend equivalent rights accrue when and as dividends are paid on the common shares underlying the applicable performance based restricted share units and vest proportionately with and are subject to settlement and expiration upon the same terms as the performance based restricted share units to which they relate.
• F10: These restricted share units vest in equal annual installments. The remaining vestings will occur on December 15, 2026, December 15, 2027 and December 15, 2028.
• F11: The shares reported represent an award of performance based restricted share units ("2025 PBRSUs") granted to the Reporting Person. The 2025 PBRSUs will have a performance period beginning on February 28, 2025 and ending on February 28, 2028 and to the extent earned will vest on March 15, 2028. The number of common shares that will be earned at the end of the performance period is subject to increase or decrease based on the results of the performance condition.
• F12: These restricted share units vest in equal annual installments. The vestings will occur on December 15, 2026, December 15, 2027, December 15, 2028 and December 15, 2029.
• F13: The shares reported represent an award of performance based restricted shares units ("2026 PBRSUs") granted to the Reporting Person. The 2026 PBRSUs will have a performance period beginning February 25, 2026 and ending February 25, 2029 and to the extent earned will vest on March 15, 2029. The number of common shares that will be earned at the end of the performance period is subject to increase or decrease based on the results of the performance condition.